PathMaker Neurosystems, founded with a mission to revolutionize the treatment of neuromotor disorders, focuses on developing non-invasive neurotechnology solutions. The company's vision is to provide effective, drug-free, and surgery-free treatments for conditions such as spasticity and ALS. Their flagship product, MyoRegulator PM-2200, utilizes multi-site direct current stimulation (DCS) technology to modulate disrupted neural pathways, offering a novel approach to neuromodulation.
Notable individuals affiliated with PathMaker Neurosystems include a distinguished management team and a scientific advisory board comprising experts in neurology and neurotechnology. The company has garnered attention for its innovative approach, receiving multiple awards and recognition in the medical community. By advancing non-invasive treatments, PathMaker Neurosystems aims to significantly impact the lives of patients with neuromotor disorders, reducing reliance on traditional drug and surgical interventions.
